Welcome
Support Centre
12 March 2010 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Does vitamin D improve markers of vascular health in stroke patients?
ISRCTN ISRCTN28737567
ClinicalTrials.gov identifier
Public title Does vitamin D improve markers of vascular health in stroke patients?
Scientific title
Acronym N/A
Serial number at source Res/A107
Study hypothesis That a single dose of oral vitamin D can lower blood pressure and improve endothelial function in stroke patients
Ethics approval Ethics approval received from the Tayside Local Research Ethics Committee on the 14th May 2007 (ref: 07/S1401/41).
Study design Double blind, randomised, placebo controlled trial.
Countries of recruitment United Kingdom
Disease/condition/study domain Stroke
Participants - inclusion criteria 1. Clinical diagnosis of completed stroke (ischaemic or haemorrhagic)
2. Serum 25-hydroxy vitamin D level less than 50 nmol/L
Participants - exclusion criteria 1. Hyper- or hypocalcaemia
2. Metastatic malignancy
3. Liver function tests over three times limit of normal
4. Estimated glomerular filtration rate (GFR) less than 40 ml/min
5. Previous clinical diagnosis of osteomalacia
6. Taking vitamin D preparations
7. Unable to give written informed consent
8. Unable to swallow tablets orally
9. Atrial fibrilation (to provide a more homogeneous aetiology)
Anticipated start date 01/06/2007
Anticipated end date 30/11/2008
Status of trial Completed
Patient information material
Target number of participants 68 (two groups of 34)
Interventions A single oral dose of 100,000 U ergocalciferol (vitamin D) or placebo.
Primary outcome measure(s) Blood pressure (seated office and 24 hour measurements) will be measured at baseline and then at 8 and 16 weeks after vitamin D administration.
Secondary outcome measure(s) The secondary outcomes will also be measured at baseline and then at 8 and 16 weeks after vitamin D administration.

1. Endothelial function
2. B-type natriuretic peptide
3. Heart rate variability
Sources of funding Chest Heart and Stroke Scotland (UK)
Trial website
Publications
Contact name Dr  Miles  Witham
  Address Department of Medicine & Therapeutics
University of Dundee
Ninewells Hospital & Medical School
  City/town Dundee
  Zip/Postcode DD1 9SY
  Country United Kingdom
  Tel +44 (0)1382 632436
  Fax +44 (0)1382 660675
  Email m.witham@dundee.ac.uk
Sponsor University of Dundee (UK)
  Address Research and Innovation Services
  City/town Dundee
  Zip/Postcode DD1 4HN
  Country United Kingdom
  Tel +44 (0)1382 384664
  Fax +44 (0)1382 386765
  Email j.z.houston@dundee.ac.uk
Date applied 21/02/2007
Last edited 28/04/2008
Date ISRCTN assigned 01/05/2007
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© ISRCTN


BioMed Central